Xi Cheng

1.4k total citations · 2 hit papers
30 papers, 923 citations indexed

About

Xi Cheng is a scholar working on Surgery, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Xi Cheng has authored 30 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 12 papers in Reproductive Medicine and 10 papers in Obstetrics and Gynecology. Recurrent topics in Xi Cheng's work include Ovarian cancer diagnosis and treatment (11 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Xi Cheng is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Xi Cheng collaborates with scholars based in China, United States and Canada. Xi Cheng's co-authors include Haoran Li, Xiaohua Wu, Rongyu Zang, Rong Jiang, Jie Tang, Sheng Yin, Tingyan Shi, Huijuan Yang, Huixun Jia and Dongsheng Tu and has published in prestigious journals such as Journal of Clinical Oncology, Brain Research and The Lancet Oncology.

In The Last Decade

Xi Cheng

28 papers receiving 914 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in diagnosis and treatment of metastatic cervical cancer

2016 372 citations Haoran Li, Xiaohua Wu et al. Journal of Gynecologic Oncology profile →
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

2021 131 citations Tingyan Shi, Jianqing Zhu et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xi Cheng China	13	360	283	262	262	251	30	923
Hideaki Yahata Japan	15	379 1.1×	144 0.5×	190 0.7×	544 2.1×	268 1.1×	70	1.1k
Shu Soeda Japan	14	163 0.5×	86 0.3×	205 0.8×	180 0.7×	144 0.6×	67	702
Georgia A. McCann United States	16	139 0.4×	98 0.3×	554 2.1×	145 0.6×	250 1.0×	37	897
Gianfranco Zannoni Italy	17	310 0.9×	94 0.3×	169 0.6×	316 1.2×	148 0.6×	42	697
Kiyoko Umene Japan	18	158 0.4×	89 0.3×	109 0.4×	155 0.6×	397 1.6×	32	841
Wen Gao China	13	183 0.5×	162 0.6×	225 0.9×	56 0.2×	187 0.7×	51	717
K Noda Japan	15	133 0.4×	171 0.6×	259 1.0×	99 0.4×	150 0.6×	45	636
Elizabeth K. Lee United States	13	152 0.4×	55 0.2×	309 1.2×	64 0.2×	205 0.8×	34	662
Daniel Donato United States	13	172 0.5×	168 0.6×	140 0.5×	271 1.0×	102 0.4×	29	532

Countries citing papers authored by Xi Cheng

Since Specialization

Citations

This map shows the geographic impact of Xi Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi Cheng more than expected).

Fields of papers citing papers by Xi Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi Cheng. The network helps show where Xi Cheng may publish in the future.

Co-authorship network of co-authors of Xi Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Xi Cheng. A scholar is included among the top collaborators of Xi Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi Cheng. Xi Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Xi, et al.. (2025). Efferocytosis-related gene IL33 predicts prognosis and immune response and mediates proliferation and migration in vitro and in vivo of breast cancer. Frontiers in Pharmacology. 16. 1533571–1533571. 2 indexed citations

Cheng, Xi, et al.. (2025). An FPGA-Based Event-Driven SNN Accelerator for DVS Applications With Structured Sparsity and Early-Stop. IEEE Transactions on Circuits and Systems I Regular Papers. 72(7). 3298–3310. 1 indexed citations

Cheng, Xi, et al.. (2025). Decoding plant thermosensors: mechanism of temperature perception and stress adaption. Frontiers in Plant Science. 16. 1560204–1560204. 3 indexed citations

Li, Haoran, et al.. (2024). Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study. Journal of Gynecologic Oncology. 36(3). e42–e42.

Zang, Rongyu, Jianqing Zhu, Jihong Liu, et al.. (2024). Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 5520–5520. 1 indexed citations

Cheng, Xi, Yulin Tan, Lin Zhuang, et al.. (2022). A novel difficulty scoring system of laparoscopic liver resection for liver tumor. Frontiers in Oncology. 12. 1019763–1019763. 4 indexed citations

Shi, Tingyan, Jianqing Zhu, Yanling Feng, et al.. (2021). Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 22(4). 439–449. 131 indexed citations breakdown →

Zhao, Chuansheng, Shanshan Zhao, Xi Cheng, et al.. (2020). Forced forelimb use following stroke enhances oligodendrogenesis and functional recovery in the rat. Brain Research. 1746. 147016–147016. 2 indexed citations

Liu, Guobing, Hongyan Yin, Xi Cheng, et al.. (2020). Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes. Clinical and Experimental Medicine. 21(1). 129–138. 15 indexed citations

10.

Shi, Tingyan, Rong Jiang, Jinjin Yu, et al.. (2018). Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. British Journal of Cancer. 119(1). 12–18. 7 indexed citations

11.

Liu, Gang, Lihua Chen, He Ren, et al.. (2018). Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma. International Journal of Biological Sciences. 14(14). 2012–2022. 10 indexed citations

12.

Shi, Tingyan, Rong Jiang, Pan Wang, et al.. (2017). Significant association of the EXO1 rs851797 polymorphism with clinical outcome of ovarian cancer. OncoTargets and Therapy. Volume 10. 4841–4851. 12 indexed citations

13.

Li, Haoran, Xiaohua Wu, & Xi Cheng. (2016). Advances in diagnosis and treatment of metastatic cervical cancer. Journal of Gynecologic Oncology. 27(4). e43–e43. 372 indexed citations breakdown →

14.

Ren, Yu, Rong Jiang, Sheng Yin, et al.. (2015). Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer. 15(1). 583–583. 33 indexed citations

15.

Cheng, Xi. (2012). Current management of patients with primary melanoma of the vagina and literature review. Zhongguo aizheng zazhi. 1 indexed citations

16.

Shi, Tingyan, Jing He, Zhi Ming Shao, et al.. (2012). Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Human Genetics. 132(3). 301–312. 38 indexed citations

17.

Cheng, Xi, et al.. (2009). Recurrence Patterns and Prognostic Factors in Chinese Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Surgery. International Journal of Gynecological Cancer. 19(1). 158–162. 13 indexed citations

18.

Jiang, Rong, Jie Tang, Xi Cheng, & Rongyu Zang. (2008). Surgical treatment for patients with different origins of Krukenberg tumors: Outcomes and prognostic factors. European Journal of Surgical Oncology. 35(1). 92–97. 79 indexed citations

19.

Cheng, Xi, et al.. (2007). Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases. International Journal of Gynecological Cancer. 18(4). 779–784. 13 indexed citations

20.

Cheng, Xi, et al.. (2004). The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World Journal of Surgical Oncology. 2(1). 47–47. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact